Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03039114|
Recruitment Status : Completed
First Posted : February 1, 2017
Last Update Posted : December 2, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma||Drug: Parsaclisib Drug: Hexal Drug: Gazyvaro||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)|
|Actual Study Start Date :||February 15, 2017|
|Actual Primary Completion Date :||March 30, 2021|
|Actual Study Completion Date :||March 30, 2021|
|Experimental: Parsaclisib + Hexal and Gazyvaro||
Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
Other Name: INCB050465
Bendamustine 90 mg/m^2 administered intravenously at protocol-defined timepoints.
Other Name: Bendamustine
Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
- Safety and tolerability of parsaclisib in combination with bendamustine and obinutuzumab in relapsed or refractory FL, assessed by number of subjects with adverse events (AEs) [ Time Frame: Screening through 30-35 days after end of treatment, up to approximately 34 months per subject ]
- Objective response rate based on Lugano classification criteria [ Time Frame: Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject ]Defined as percentage of subjects with a complete response (CR) and partial response (PR), as determined by investigator assessment of response
- Complete response rate based on Lugano classification criteria [ Time Frame: Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject ]Defined as percentage of subjects who achieve a best overall response of CR
- Duration of response [ Time Frame: Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject ]Defined as time from first documented evidence of CR or PR until earliest date of disease progression or death due to any cause.
- Progression-free survival [ Time Frame: Protocol-defined timepoints throughout the treatment period, up to approximately 34 months per subject ]Defined as time from the date of the first dose of study drug until the earliest date of disease progression (determined by radiographic disease assessment/Lugano classification criteria) or death due to any cause.
- Overall survival [ Time Frame: From the date of the first dose of study drug until death due to any cause, assessed up to approximately 34 months per subject ]Defined as the time from the date of the first dose of study drug until death due to any cause.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically confirmed FL.
- Documented CD20+ FL.
- Relapsed or refractory to any prior rituximab-containing regimen.
- Previously treated with a maximum of 4 cancer-directed treatment regimens.
- At least 1 measurable lesion > 1.5 cm in at least 1 dimension by computed tomography or magnetic resonance imaging.
- Must be willing to undergo an incisional or excisional lymph node biopsy of accessible adenopathy or provide the most recent, available archived tumor biopsy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Clinical evidence of transformation to a more aggressive subtype of lymphoma or Grade 3B FL.
- History of central nervous system lymphoma (either primary or metastatic).
- Allogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug administration.
- Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug.
- Prior treatment with a selective PI3Kδ inhibitor or a pan PI3K inhibitor.
Prior treatment with bendamustine (within 12 months of the start of study treatment). Subjects with prior bendamustine treatment (> 12 months before the start of study treatment) are eligible if they meet the following criteria:
- Did not discontinue because of tolerability concerns.
- Achieved either partial or CR to the bendamustine regimen of at least 12 months in duration before relapse/progression.
- Experienced progression following a regimen containing an alkylating agent.
- Received prior obinutuzumab.
- Received rituximab within 4 weeks of study start.
- Prior treatment-related toxicities that have not resolved to ≤ Grade 1 before the date of study drug administration except for stable chronic toxicities (≤ Grade 2) not expected to resolve (eg, stable Grade 2 peripheral neurotoxicity).
- Received any prior monoclonal antibody (except an anti-CD20 antibody) within 90 days before the date of study start.
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (eg, subjects in whom re-administration with rituximab would be contraindicated for safety reasons).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03039114
|Study Director:||Fitzroy Dawkins, MD||Incyte Corporation|
|Responsible Party:||Incyte Corporation|
|Other Study ID Numbers:||
INCB 50465-102 (CITADEL-102)
Parsaclisib ( Other Identifier: Incyte Corporation )
|First Posted:||February 1, 2017 Key Record Dates|
|Last Update Posted:||December 2, 2021|
|Last Verified:||December 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
phosphatidylinositol 3-kinase (PI3K)
Neoplasms by Histologic Type
Immune System Diseases
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological